Literature DB >> 18758459

miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis.

Yoontae Lee1, Rodney C Samaco, Jennifer R Gatchel, Christina Thaller, Harry T Orr, Huda Y Zoghbi.   

Abstract

Spinocerebellar ataxia type 1 is caused by expansion of a translated CAG repeat in ataxin1 (ATXN1). The level of the polyglutamine-expanded protein is one of the factors that contributes to disease severity. Here we found that miR-19, miR-101 and miR-130 co-regulate ataxin1 levels and that their inhibition enhanced the cytotoxicity of polyglutamine-expanded ATXN1 in human cells. We provide a new candidate mechanism for modulating the pathogenesis of neurodegenerative diseases sensitive to protein dosage.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18758459      PMCID： PMC2574629          DOI： 10.1038/nn.2183

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN： 1097-6256            Impact factor:   24.884


  15 in total

1.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

Review 2.  Trinucleotide repeat disorders.

Authors:  Harry T Orr; Huda Y Zoghbi
Journal:  Annu Rev Neurosci       Date:  2007       Impact factor: 12.449

3.  Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human.

Authors:  D P Huynh; K Figueroa; N Hoang; S M Pulst
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

4.  YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit.

Authors:  Cemal K Cemal; Christopher J Carroll; Lorraine Lawrence; Margaret B Lowrie; Piers Ruddle; Sahar Al-Mahdawi; Rosalind H M King; Mark A Pook; Clare Huxley; Susan Chamberlain
Journal:  Hum Mol Genet       Date:  2002-05-01       Impact factor: 6.150

5.  SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat.

Authors:  E N Burright; H B Clark; A Servadio; T Matilla; R M Feddersen; W S Yunis; L A Duvick; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1995-09-22       Impact factor: 41.582

6.  Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1.

Authors:  H T Orr; M Y Chung; S Banfi; T J Kwiatkowski; A Servadio; A L Beaudet; A E McCall; L A Duvick; L P Ranum; H Y Zoghbi
Journal:  Nat Genet       Date:  1993-07       Impact factor: 38.330

7.  RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.

Authors:  Haibin Xia; Qinwen Mao; Steven L Eliason; Scott Q Harper; Inês H Martins; Harry T Orr; Henry L Paulson; Linda Yang; Robert M Kotin; Beverly L Davidson
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

8.  Prediction of mammalian microRNA targets.

Authors:  Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

9.  Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1.

Authors:  Janghoo Lim; Juan Crespo-Barreto; Paymaan Jafar-Nejad; Aaron B Bowman; Ronald Richman; David E Hill; Harry T Orr; Huda Y Zoghbi
Journal:  Nature       Date:  2008-03-12       Impact factor: 49.962

10.  Cerebellar neurodegeneration in the absence of microRNAs.

Authors:  Anne Schaefer; Dónal O'Carroll; Chan Lek Tan; Dean Hillman; Mutsuyuki Sugimori; Rodolfo Llinas; Paul Greengard
Journal:  J Exp Med       Date:  2007-07-02       Impact factor: 14.307
View more
  100 in total

1.  Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2.

Authors:  Yu Miyazaki; Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Yue-Mei Jiang; Zhe Huang; Hideki Doi; Shinjiro Matsumoto; Naohide Kondo; Madoka Iida; Genki Tohnai; Fumiaki Tanaka; Shin-ichi Muramatsu; Gen Sobue
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

Review 2.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 3.  Non-coding RNAs in human disease.

Authors:  Manel Esteller
Journal:  Nat Rev Genet       Date:  2011-11-18       Impact factor: 53.242

4.  MicroRNA-130a represses transcriptional activity of aquaporin 4 M1 promoter.

Authors:  Sugunavathi Sepramaniam; Lim Kai Ying; Arunmozhiarasi Armugam; E M Wintour; Kandiah Jeyaseelan
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

5.  MicroRNA-101 downregulates Alzheimer's amyloid-β precursor protein levels in human cell cultures and is differentially expressed.

Authors:  Justin M Long; Debomoy K Lahiri
Journal:  Biochem Biophys Res Commun       Date:  2010-12-21       Impact factor: 3.575

Review 6.  Role of noncoding RNAs in trinucleotide repeat neurodegenerative disorders.

Authors:  Huiping Tan; Zihui Xu; Peng Jin
Journal:  Exp Neurol       Date:  2012-01-27       Impact factor: 5.330

Review 7.  MicroRNAs in neurodegenerative diseases and their therapeutic potential.

Authors:  Eunsung Junn; M Maral Mouradian
Journal:  Pharmacol Ther       Date:  2011-10-08       Impact factor: 12.310

Review 8.  SCA1-phosphorylation, a regulator of Ataxin-1 function and pathogenesis.

Authors:  Harry T Orr
Journal:  Prog Neurobiol       Date:  2012-04-16       Impact factor: 11.685

Review 9.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

Review 10.  Understanding microRNAs in neurodegeneration.

Authors:  Stephen M Eacker; Ted M Dawson; Valina L Dawson
Journal:  Nat Rev Neurosci       Date:  2009-11-11       Impact factor: 34.870
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.